JP2005528378A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005528378A5 JP2005528378A5 JP2003581846A JP2003581846A JP2005528378A5 JP 2005528378 A5 JP2005528378 A5 JP 2005528378A5 JP 2003581846 A JP2003581846 A JP 2003581846A JP 2003581846 A JP2003581846 A JP 2003581846A JP 2005528378 A5 JP2005528378 A5 JP 2005528378A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- component
- susceptible
- treating
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 206010061284 Mental disease Diseases 0.000 claims 9
- QZUDBNBUXVUHMW-UHFFFAOYSA-N Clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims 4
- KVWDHTXUZHCGIO-UHFFFAOYSA-N Olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 4
- 229960004170 clozapine Drugs 0.000 claims 4
- 229960005017 olanzapine Drugs 0.000 claims 4
- 102100006616 GRM2 Human genes 0.000 claims 3
- 101700061690 GRM2 Proteins 0.000 claims 3
- 239000003693 atypical antipsychotic agent Substances 0.000 claims 3
- VTAARTQTOOYTES-UHFFFAOYSA-N 2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid Chemical group OC(=O)C1(N)CCC2C(C(O)=O)C12 VTAARTQTOOYTES-UHFFFAOYSA-N 0.000 claims 2
- CGPYNUAPVFBCFD-UHFFFAOYSA-N 2-oxabicyclo[3.1.0]hexane Chemical compound C1COC2CC21 CGPYNUAPVFBCFD-UHFFFAOYSA-N 0.000 claims 2
- 102100006614 GRM3 Human genes 0.000 claims 2
- 101700043312 GRM3 Proteins 0.000 claims 2
- KGLBEZVXEHOXRV-UHFFFAOYSA-N NC12C(CCC2C1)=S(=O)=O Chemical compound NC12C(CCC2C1)=S(=O)=O KGLBEZVXEHOXRV-UHFFFAOYSA-N 0.000 claims 2
- 206010037175 Psychiatric disease Diseases 0.000 claims 2
- 150000001875 compounds Chemical group 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- WLYANNSIDDXEGE-GWGQIBMDSA-N (1S,2R,4S,5S,6S)-2-amino-4-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid Chemical group OC(=O)[C@@]1(N)C[C@H](F)[C@@H]2[C@@H](C(O)=O)[C@H]12 WLYANNSIDDXEGE-GWGQIBMDSA-N 0.000 claims 1
- WLYANNSIDDXEGE-DGIVVOJNSA-N (1S,2R,4S,6S)-2-amino-4-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid Chemical group OC(=O)[C@@]1(N)C[C@H](F)C2[C@@H](C(O)=O)[C@H]12 WLYANNSIDDXEGE-DGIVVOJNSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
Claims (22)
24. A pharmaceutical composition according to claim 21 for treating a patient suffering from or susceptible to a mental disorder.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36977102P | 2002-04-03 | 2002-04-03 | |
| US36979702P | 2002-04-03 | 2002-04-03 | |
| PCT/US2003/007283 WO2003084610A1 (en) | 2002-04-03 | 2003-03-21 | Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005528378A JP2005528378A (en) | 2005-09-22 |
| JP2005528378A5 true JP2005528378A5 (en) | 2006-04-27 |
Family
ID=28794376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003581846A Pending JP2005528378A (en) | 2002-04-03 | 2003-03-21 | Psychiatric treatment combining atypical antipsychotic and mGLU2 / 3 receptor agonist |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1492595A1 (en) |
| JP (1) | JP2005528378A (en) |
| AU (1) | AU2003218063A1 (en) |
| CA (1) | CA2478227A1 (en) |
| WO (1) | WO2003084610A1 (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ556437A (en) | 2002-06-11 | 2008-11-28 | Lilly Co Eli | Prodrugs of excitatory amino acids |
| AU2008200612B8 (en) * | 2002-06-11 | 2011-03-10 | Eli Lilly And Company | Prodrugs of excitatory amino acids |
| AR059898A1 (en) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | DERIVATIVES OF 3-CIANO-PIRIDONA 1,4-DISUSTITUTED AND ITS USE AS ALLOSTERIC MODULATORS OF MGLUR2 RECEIVERS |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| NZ584145A (en) | 2007-09-14 | 2012-03-30 | Ortho Mcneil Janssen Pharm | 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1,4'] bipyridinyl-2'-ones |
| ES2439291T3 (en) | 2008-09-02 | 2014-01-22 | Janssen Pharmaceuticals, Inc. | 3-Azabicyclo [3.1.0] hexyl derivatives as modulators of metabotropic glutamate receptors |
| MX2011005242A (en) | 2008-11-28 | 2011-09-06 | Ortho Mcneil Janssen Pharm | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors. |
| MY161325A (en) | 2009-05-12 | 2017-04-14 | Janssen Pharmaceuticals Inc | 1, 2, 4-triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders |
| CA2760259C (en) | 2009-05-12 | 2018-05-01 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| JP5852664B2 (en) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of the mGluR2 receptor |
| CN103298809B (en) | 2010-11-08 | 2016-08-31 | 杨森制药公司 | 1,2,4-triazol [4,3-a] pyridine derivate and the purposes of the positive allosteric modulators as MGLUR2 acceptor thereof |
| ES2536433T3 (en) | 2010-11-08 | 2015-05-25 | Janssen Pharmaceuticals, Inc. | 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
| AU2012271024B2 (en) | 2011-06-17 | 2015-07-09 | Eli Lilly And Company | Bicyclo (3.1.0) hexane- 2, 6 -dicarboxylic acid derivatives as mGlu2 receptor agonist |
| EP2919788A4 (en) | 2012-11-14 | 2016-05-25 | Univ Johns Hopkins | Methods and compositions for treating schizophrenia |
| JO3368B1 (en) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| JO3367B1 (en) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| ME03518B (en) | 2014-01-21 | 2020-04-20 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
| WO2015110435A1 (en) | 2014-01-21 | 2015-07-30 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5955459A (en) * | 1997-11-26 | 1999-09-21 | Neuromedica, Inc. | Fatty acid-antipsychotic compositions and uses thereof |
-
2003
- 2003-03-21 AU AU2003218063A patent/AU2003218063A1/en not_active Abandoned
- 2003-03-21 WO PCT/US2003/007283 patent/WO2003084610A1/en active Application Filing
- 2003-03-21 CA CA002478227A patent/CA2478227A1/en not_active Abandoned
- 2003-03-21 JP JP2003581846A patent/JP2005528378A/en active Pending
- 2003-03-21 EP EP03714045A patent/EP1492595A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005528378A5 (en) | ||
| Abram et al. | Chirality as an important factor for the development of new antiepileptic drugs | |
| ES2977383T3 (en) | Neuroattenuating norketamine compounds and methods | |
| HRP20110570T1 (en) | Nicotinic acetylcholine receptorsub-type selective amides of diazabicycloalkanes | |
| US20050288375A1 (en) | Method and composition for treating neurodegenerative disorders | |
| RU2016122563A (en) | TETRAHYDROBENZODIAZEPINONES | |
| IL169954A (en) | Tricyclo substituted amide compounds, process for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for the treatment of a condition where activation of gk is desirable | |
| WO2012018499A2 (en) | Specific regulation of cytokine levels by hdac6 inhibitors | |
| EP2213684A3 (en) | Nogo-a antibodies for the treatment of Alzheimer disease | |
| JP2008539250A (en) | Methods for treating atherosclerosis | |
| JP2011520981A5 (en) | ||
| SG151336A1 (en) | 1,3,4-oxadiazol-2-ones as ppar delta | |
| CN106604747A (en) | Products for the treatment and prevention of neurological disorders coursing with a cognition deficit or impairment, and of neurodegenerative diseases | |
| IL179160A0 (en) | Substituted n-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies | |
| WO2005027977A3 (en) | Diclofenac compositions for the treatment of skin disorders | |
| FR2851163B1 (en) | USE OF DEXTROGYAN ENANTIOMER OF MILNACIPRAN FOR THE PREPARATION OF A MEDICINAL PRODUCT | |
| RU2011123862A (en) | GAMMA SECRETASE MODULATORS | |
| NZ603207A (en) | Combination of hmg-coa reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases | |
| JP2004517824A5 (en) | ||
| MX2011011490A (en) | Isoxazole-thiazole derivatives as gaba a receptor inverse agonists for use in the treatment of cognitive disorders. | |
| AR062112A1 (en) | CYCLE DERIVATIVES AS MODULATORS OF THE ACTIVITY OF THE CHEMIOKIN RECEPTOR | |
| EA202190334A1 (en) | PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION WITH MODIFIED RELEASE | |
| WO2005092062A3 (en) | Compounds for neurodegenerative disorders | |
| WO2003077832A3 (en) | Dexanabinol and dexanabinol analogs regulate inflammation related genes | |
| WO2005123068A3 (en) | Methods of dealying alzheimer’s disease progression using a beta-amyloid precursor protein inhibitor and a hmg coa reductase inhibitor |